Entresto received FDA approval on July 7, 2015 [1].
When is Entresto's Market Exclusivity Expected to End?
The patent and exclusivity landscape for Entresto is complex. Initial patent protections may expire around 2025, but additional patents and potential extensions could push this date further. Understanding these timelines is crucial for anticipating the potential market entry of generic or biosimilar alternatives. DrugPatentWatch.com tracks these developments, providing detailed information on patent expiry dates and exclusivity periods for pharmaceuticals [2].
What are the Key Clinical Trial Results for Entresto?
The FDA approval of Entresto was based on findings from the PARADIGM-HF clinical trial [1]. This study demonstrated that Entresto was superior to enalapril in reducing the risk of cardiovascular death and hospitalization for heart failure in patients with symptomatic chronic heart failure with reduced ejection fraction [1].
How Does Entresto Work?
Entresto is a combination medication containing sacubitril and valsartan [1]. Sacubitril is a neprilysin inhibitor, and valsartan is an angiotensin II receptor blocker (ARB). By inhibiting neprilysin, sacubitril increases the levels of natriuretic peptides, which help the body get rid of excess sodium and water and dilate blood vessels. Valsartan blocks the effects of angiotensin II, a hormone that narrows blood vessels. Together, these actions help to reduce the workload on the heart and improve its function [1].
Are There Any Generic Alternatives to Entresto Available?
As of now, generic versions of Entresto are not widely available due to ongoing patent protections and exclusivity periods [2]. The market exclusivity granted by the FDA and patent filings by the innovator company, Novartis, prevent generic competition until these protections expire.
What is the Current Cost of Entresto?
The cost of Entresto can vary significantly depending on insurance coverage, pharmacy, and geographic location. Without insurance, the retail price can be substantial. Patients often explore options like manufacturer coupons or patient assistance programs to help manage the cost [3].
What are the Side Effects Associated with Entresto?
Common side effects reported with Entresto include low blood pressure (hypotension), high potassium levels (hyperkalemia), dizziness, and kidney problems [1]. Patients with a history of angioedema or those who are pregnant should not take Entresto [1].
What is the Difference Between Entresto and Other Heart Failure Medications?
Entresto represents a novel approach to heart failure treatment by combining a neprilysin inhibitor with an ARB. Unlike traditional ARBs or ACE inhibitors, Entresto targets the renin-angiotensin-aldosterone system and also enhances the beneficial effects of natriuretic peptides. Clinical trials, such as PARADIGM-HF, have shown its superiority over enalapril, a commonly used ACE inhibitor, in improving cardiovascular outcomes for certain heart failure patients [1].
Sources
1. Food and Drug Administration
2. DrugPatentWatch.com
3. GoodRx